US 12,083,147 B2
Compositions and methods for the treatment of contact lens discomfort
Charles Bosworth, Las Vegas, NV (US); Yair Alster, Tel Aviv (IL); Hila Epstein-Barash, Shoham (IL); Omer Rafaeli, Udim (IL); and Marc Gleeson, Longueville (AU)
Assigned to AZURA OPHTHALMICS LTD., Tel Aviv (IL)
Filed by Azura Ophthalmics Ltd., Tel Aviv (IL)
Filed on Apr. 18, 2022, as Appl. No. 17/723,090.
Application 17/723,090 is a continuation of application No. 17/357,749, filed on Jun. 24, 2021, granted, now 11,324,775.
Application 17/357,749 is a continuation of application No. PCT/IB2020/000262, filed on Apr. 8, 2020.
Claims priority of provisional application 62/833,281, filed on Apr. 12, 2019.
Prior Publication US 2022/0233584 A1, Jul. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/04 (2006.01); A61P 27/04 (2006.01); G02C 7/04 (2006.01)
CPC A61K 33/04 (2013.01) [A61P 27/04 (2018.01); G02C 7/04 (2013.01)] 20 Claims
 
1. A method for improving vision in an individual wearing a contact lens, the method comprising:
(i) topically administering to an eye or an eyelid associated with the eye of the individual a pharmaceutically acceptable composition, the composition comprising a therapeutically-effective amount of at least one keratolytic agent and an ophthalmically-acceptable carrier; and
(ii) wearing a contact lens in the eye, wherein vision of the individual is improved relative to vision of the individual in the absence of the topical administration of the composition, and wherein the individual has not been diagnosed with meibomian gland dysfunction (MGD).